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Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and
modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells
transfected with thymidine phosphorylase
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Summary Platelet-derived endothelial cell growth factor (PD-ECGF) is identical to human thymidine phos-
phorylase (dThdPase). The human MCF-7 breast cancer cell line was transfected with the dThdPase cDNA
and expressed a 45 kDa protein that was detected with anti-dThdPase antibody. Cell lysates possessed elevated
dThdPase activity and cells had up to 165-fold increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine
(5'-DFUR) in vitro. Sensitivity to 5-fluorouracil (5-FU) and 5-fluoro-2'-deoxyuridine (5-FUdR) was
unchanged. Recombinant dThdPase was shown to catalyse directly the phosphorolytic cleavage of 5'-DFUR
to 5-FU. Exogenous thymidine (dThd) reversed the toxicity of 5-FUdR on the parental line (1 JAM dThd
increased the IC50 value 1000-fold), but the dThd rescue was substantially modulated in the dThdPase-
expressing clone 4 (1 gM dThd raised the IC50 value 3-fold). We observed a substantial 'bystander' killing effect
when small proportions of dThdPase-expressing cells were mixed with parental MCF-7 cells. dThdPase activity
was on average 27-fold higher in breast tumours than in normal breast. The levels in wild-type MCF-7 are
similar to the low end of the tumour expression. Thus, in some tumours resistance to 5'-DFUR therapy could
be due to low dThdPase activity, and transfection to raise the dThdPase. levels within the broad tumour range
or above it should markedly enhance sensitivity to the prodrug. These results confirm that dThdPase is a
major pathway in the metabolic activation of 5'-DFUR, and the bystander effect suggests that this may be a
suitable enzyme for gene therapy-directed enzyme/prodrug activation therapy.
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Platelet-derived endothelial cell growth factor (PD-ECGF)
was originally isolated from platelets through its unique
mitogenic activity on endothelial cells (Miyazono et al., 1987;
1989). It has since been shown to be homologous to human
thymidine phosphorylase and a product of the same gene
(Furukawa et al., 1992). Thymidine phosphorylase (dThd-
Pase) (EC 2.4.2.4.) catalyses the reversible phosphorolytic
cleavage of thymidine (dThd), deoxyuridine and their
analogues to their bases and deoxyribose 1-phosphate (Il-
tzsch et al., 1985; el Kouni et al., 1993). However, while
evidence strongly implicates dThdPase in the metabolic
activation of 5'-deoxy-5-fluorouridine (5'-DFUR) (Fujimoto
et al., 1985), no study has definitively demonstrated that pure
human dThdPase can phosphorolytically cleave the glycosidic
bond of the prodrug 5'-DFUR to yield 5-fluorouracil (5-FU).
We show here that elevated expression of dThdPase sensitises
MCF-7 breast cancer cells to 5'-DFUR and this sensitisation
is related to the capacity of dThdPase to cleave 5'-DFUR to
5-FU.
Breast, ovarian, colorectal and gastric cancers have been
shown to express elevated levels of dThdPase relative to the
normal surrounding tissue (Zimmerman et al., 1964; Yoshi-
mura et al., 1990). Increased dThdPase activity has also been
found in the plasma of cancer patients compared with heal-
thy controls (Pauly et al., 1977, 1978). This tumour-
associated elevation of dThdPase activity has been exploited
clinically through use of the prodrug 5'-DFUR. Yet success
has been limited, possibly because of the heterogeneity of
dThdPase activity within this group of carcinomas. Greater
exploitation of this 'enzyme-prodrug activation' model could
be achieved through the application of gene therapy tech-
niques to direct the tissue-specific expression of dThdPase
(Vile et al., 1993a). For example, in vivo transfection of
cDNA sequences by direct intratumoral injection induces a
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small proportion of the tumour cell population to transiently
express the construct (Vile et al., 1993b).
We investigated the possibility that tumours expressing a
low basal level of dThdPase activity might be further sen-
sitised to 5'-DFUR through the transfection and expression
of dThdPase, and whether elevated expression within a small
proportion of the cell population could sensitise neighbour-
ing tumour cells to the prodrug.
Comparative sensitivities of the parental and transfected
cell lines to 5'-DFUR, 5-FU and 5-fluoro-2'-deoxyuridine
(5-FUdR) were examined in the presence and absence of
exogenous dThd. The presence of salvageable dThd within
the microenvironment of a tumour could reduce the efficiency
of the prodrug-enzyme system, since dThd will compete with
its analogue 5'-DFUR for the active site of dThdPase, and
limits its cytotoxic effects. Furthermore, dThdPase may
enhance the toxicity of the active drug 5-FU, by deoxyribosyl
transfer of 2'-deoxyribose 1-phosphate (Zimmerman et al.,
1964; Krenitsky, 1968), producing the deoxynucleoside 5-
FUdR, which can form 5-FdUMP through the action of
thymidine kinase, 5-FdUMP can inhibit thymidylate syn-
thase, restricting de novo synthesis of dTMP, and can
ultimately be fraudulently incorporated into DNA (Schwartz
et al., 1992). If the cytotoxic effects of 5-FU are mediated in
part by this pathway, bioavailable dThd would diminish any
inhibitory effects of thymidylate synthase inhibition.
Materials and methods
Chemicals
Thymine, dThd, 5-FU, 5-FUdR and MTT (3-[4,5-dim-
ethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) were pur-
chased from Sigma (Dorset, UK). 5'-Deoxy-5-fluorouridine
(5'-DFUR) was a kind gift from Dr Hideo Ishitsuka, Nippon
Roche KK (Kanagawa, Japan).MCF-7 edshmanectd with dThdPms* s=ml msd5' V5 f etg
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Preparation ofanti-dThdPase antiboy
Recombinant dThdPase protein, expressed as a glutathione
S-transferase (GST) fusion protein in Escherichia coli, was
purified and proteolytically cleaved with thrombin to remove
the GST leader peptide (Moghaddam et al., 1992). The
cleaved protein was used to generate anti-dTbdPase antisera.
Adjuvant preparations, immunisations and bleeding of the
animals were carried out using a standard rabbit immunisa-
tion protocol.
Cell lines
Human MCF-7 breast cell lines and clones 4 and 7 were
grown in E4 modified minimal essential medium (prepared at
ICRF, Clare Hall, Cambridge, UK) supplemented with 10%
fetal calf serum and 4mM glutamine. Cells were routinely
screened and found free of Mycoplasma.
Transfection ofdThdPase cDNA into MCF-7 cells
The details of generation and characterisation are to be
published (H Zhang and R Bicknell, manuscript in prepara-
tion). Briefly, pS' plasmid vector containing full-length
dThdPase DNA was introduced into MCF-7 cells by elec-
troporation. Stable transfectants were selected by long-term
incubation in G418.
Determination ofdoubling times ofMCF-7 and cloned cell
lines
Cells were incubated in 96-well format, at a density of
5 x 10' cells per well. At the times indicated, cells were
incubated with 0.1mg (50#lI of 2 mgml-') of MiT for 4h,
and cell number was determined by reference to standard
absorption curves ofpredetermined cell numbers for each cell
line.
Quantitation ofdrug sensitivity
The modified MiT assay (Carmichael et al., 1987) was used
to determine the dose-response curves of the parental and
clone cell lines, using a multiwell spectrophotometer (Titretek
Multiskan Plus MKH, Flow Laboratories). ICso values were
determined relative to control wells containing no drug, usng
Deltasoft software (Biometallics, Princeton, NJ, USA). Cells
were seeded at 5 x 10' per well and left for 3 h before drug
application. All incubations were 7 days.
Preparation ofcell lysates
MCF-7 and cloned lines were harvested in exponential
growth phase by trypsinisation, washed in phosphate-buff-
ered saline (PBS), and sonicated in 50 mM Tris-HC, 0.15 M
sodium chloride buffer, Ph 7.4, at 4C. Suspension was cen-
trifuged at 10000 g for 15 min (4C). Supernatants were
stored in liquid nitrogen and assayed for dThdPase activity.
Preparation ofbreast tissue cytosols
Breast tissue was removed during primary biopsy and stored
in liquid nitrogen until preparation. Samples were ground by
pestle and mortar in the presence of liquid nitrogen before
automated homogenisation in 50 mM Tris-HCI, 0.15 M
sodium chloride buffer, pH 7.4, at 4-C. Cell debris was
removed by spinning at 300 g for 10 min (4C). The resulting
supernatant was spun at 100 000 g for 40 min (4C) and
stored at - 80C.
Assay ofdThdPase activity
Lysates were incubated for 16 h at 3TC in 10 mM dThd or
5'-DFUR and 10 mm potassium phosphate, pH 7.4. The
reaction was terminated by addition of 0.7 ml of ice-cold
sodium hydroxide (500 mM for dThd substrate, 20 mM for
5'-DFUR substrate) to 0.3 ml of reaction mixture, to pro-
duce a final solution pH of 13.3 and 12 respectively. Quen-
ched samples were kept on ice, and the conversion of dThd
to thymine and 5'-DFUR to 5-FU were measured spect-
rophotometrically at 300 nm and 305 nm respectively
(Schwartz, 1978; Choong and Lee, 1985). Optical densities
were related to standard plots for known thymine and 5-FU
concentrations. Protein content of the cell lysates and breast
tumour and normal tissue cytosols were determined using the
Bio-Rad protein dye assay and quantitated against high-
grade BSA protein standard. dThdPase activity is expresed
as nmol substrate converted per mg total cytosolic protein
per hour.
Immunoblot analysis
Samples of cells harvested for enzyme assays were washed in
PBS buffer containing 1 mM phenylmethylsulphonyl fluoride,
1 mM benzamide, 50 Lgml-' leupeptin and 50 lAg ml-' soya-
bean trypsin inhibitor. Cells were lysed in 1 ml of 2% SDS
plus inhibitors in PBS at 65'C for 5 min. DNA was broken
up with a fine-gauge needle passed up and down. Samples
were stored at - 20-C. Samples were resolved by 10% SDS-
polyacrylamide gel electrophoresis, and proteins on the gel
were electrophoretically transferred overnight to a nitrocel-
lulose hybridisation transfer membrane. The membrane was
washed with blocking buffer and incubated for 30 min with
specific dThdPase rabbit antibody (dilution 1:500). After
washing, horseradish peroxidase-conjugated goat anti-rabbit
antibody was incubated, and the membrane was developed
using the enhanced chiluminescence Western blotting
detection kit (Amersham, Buckinghamshire, UK).
Resut
dThdPase expression in MCF-7 cells
Two clones, 4 and 7, were selected following transfection of
MCF-7 cells with full-length dTbdPase cDNA. Cell lysates
were prepared to examine the relative ofdThdPase activity of
the parental and transfected cell lines. The release of thymine
from dThd and 5-FU from 5-DFUR were monitored spect-
roscopically at 300 nm and 305 nm respectively (Schwartz;
1978; Choong and Lee, 1985). The observed enzyme activities
of the lysates were compared with the in vitro sensitivity
assays. The parental MCF-7 cells had some endogenous
dThdPase activity, while clone 4 and clone 7 displayed a 90-
and 7-fold increase in activity respectively (Table I). Subse-
quent Western immunoblot analysis of the cell lysates
confirmed that the clones expressed elevated levels of a
45 kDa protein that was detected by an anti-dThdPase
antibody (Figure 1). Although enzyme activity could be
detected, Western blotting was not as sensitive and could not
demonstrate dThdPase in the parental MCF-7 cells. Com-
parative immunohistochemical staining of the parental and
clone cells with primary anti-dThdPase antibody labelled
with swine anti-rabbit FITC-conjugated antibody revealed
the localisation of the 45 kDa protein to be predominantly
cytoplasmic in the clonal lines.
Tae I dThdPase activities of parental and clonal cell line lysates,
with respect to both dThd and 5'-DFUR phosphorolytic cleavage
Thymidone phosphorylase actmty of cell
lysates ± s.em. at 377C
nmol thymine released nmol 5-FU released
CeUl lines mg-' protein h-' mg-' protein h-'
MCF-7 wt 38.2± 5.9 47 11.2
Clone 4 3383 133 3160 187
Clone 7 269 12.2 264 19.4
dThdPase activity (nmol of thymine or 5-FUJ released/per hour per
mg of protein) was monitored spectrophotometrically. Each value
represents the mean ± s.e.m. of at least three independent
determinations. Clones 4 and 7 are sublnes of MCF-7 cells
transfected with dThdPase cDNA.
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Figue 1 Western immunoblot of recombinant dThdPase, MCF-
7 parental line, clone 4 and clone 7 with anti-dThdPase antibody.
Both clones 4 and 7 are sublines of MCF-7 cells transfected with
dThdPase cDNA in the pS' vector. Both clones were selected by
long-term incubation in Geneticin. Lysates prepared from each
were separated by electrophoresis on a 10% sodium dodecyl
sulphate-polyacrylamide gel and transblotted onto a nitrocel-
lulose hybridisation transfer membrane. The membrane was
incubated sequentially in anti-dThdPase antibody and horse-
radish peroxidase-conjugated goat anti-rabbit antibody, and then
developed using an enhanced chemiluminescence Western blotting
detection kit.
Growth rates ofcell lines
The mean doubling times of parental MCF-7, clone 4 and
clone 7 cells were 51.4 ± 9.2, 77.1 + 14.2 and 67.5 ± 12.7 h
respectively. There was no significant difference in cellular
growth rates, indicating that elevated dThdPase expression
does not appear to affect the growth rate of the cells.
Drug sensitivity ofparental and transfected cell lines
The drug sensitivity of the cells was determined using the
MTT assay (Table II). The IC% values for 5-FU were not
significantly different between the parental line and clones 4
and 7, being 1.03, 0.73 and 1.44 1M respectively (Figure 2a).
However, the IC% values of the prodrug 5'-DFUR, which is
converted to 5-FU by dThdPase, were markedly different,
being 17.3, 0.10 and 7.1 iLM for the parental line, clone 4 and
clone 7 respectively (Figure 2b). The IC50 ratios of clone 4
and clone 7 were 165 and 2.4 times higher than that of the
parental line. The differing sensitivities of the cell lines were
reflected in their relative levels of dThdPase activity with
respect to the release of 5-FU from 5'-DFUR (Table I).
Sensitivity to 5-FUdR was not significantly different between
the parental and clonal lines.
Modulation ofdrug sensitivity by exogenous thymidine
The presence of salvageable dThd may circumvent any tox-
icity associated with the inhibition of de novo dTMP syn-
thesis. Therefore we examined the capacity of physiologically
relevant concentrations of dThd to modulate the toxicity of
5'-DFUR, 5-FU and 5-FUdR in vitro.
Co-addition of dThd during 5-FU exposure did not affect
the sensitivity of either the parental or transfected cell lines,
even at the maximum concentration (1501AM) that was non-
toxic to the cells. This suggests that thymidylate synthase
inhibition is not an important determinant for 5-FU toxicity
in these cell lines (Danenberg et al., 1974; Kufe and Major,
1981). In contrast, physiologically relevant concentrations of
dThd (1-10 1M) could partially reverse the inhibitory activity
of 5'-DFUR on clones 4 and 7. Indeed, 101AM dThd shifted
the IC-% value ofclone 4 for 5'-DFUR by 18-fold (Figure 3a).
Nevertheless, clone 4 cells were still markedly sensitised to
5'-DFUR compared with controls, and sufficiently high pro-
drug concentrations () 101AM) could overcome the dThd-
induced reversal of toxicity. However, 1-10 M dThd had no
effect on the response of the parental line to 5'-DFUR
(Figure 3b).
There was a marked capacity of exogenously added dThd
(1-3 1M) to modulate the inhibitory effects of 5-FUdR in the
parental cells which was significantly reversed in the clone
cells, particularly clone 4. This suggests that the phos-
phorolytic activity of dThdPase can reduce the intracellular
availability of dThd, reducing competition with 5-FdUTP for
MCF-7 ca ismce with dThdPas w sens&wedb 5' ,e o n
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Table H Mean IC50 values of these fluorinated pyrimidines for the
parental and clonal MCF-7 cell lines
Drug sensitivitylIC50 vahles ± s.e.m.
Drug MCF-7 wt Clone 4 Clone 7
5-FU (ILM) 1.03± 1.0 0.73±0.48 1.44±0.96
5'-DFUR (jAM) 17.3 3.1 0.104±0.032 7.1 1.7
5-FUdR (nM) 2.3 ± 0.42 2.6 ± 0.31 2.2 ± 0.7
IC50 values were determined using the MTT assay following 7
days' continuous incubation. Each value is the mean ± s.e.m. of at
least four independent experiments.
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Figure 2 (a) Representative in vitro dose-response curve of
parental MCF-7 (0), clone 4 (0) and clone 7 (A) cell lines to
5-fluorouracil. Per cent growth inhibition is relative to untreated
controls and is determined using the MTT assay. For clarity top
and bottom error bars (s.d. of eight wells) are included for clone
7 and clone 4 respectively. (b) Representative in vitro dose-
response curve of the parental MCF-7 (0), clone 4 (0) and
clone 7 (A) cell lines to the prodrug of 5-FU, 5'-deoxy-5-
fluorouridine. Per cent growth inhibition is relative to untreated
controls and is determined using the MTT assay. Error bars
represent the s.d. of eight wells.
incorporation into DNA. Indeed, 1 AiM dThd increased the
IC_, value of 5-FUdR for the parental line from 2.3 to
approximately 2400 nM, some 1000-fold (Figure 4a), while
producing only a 3-fold reversal of toxicity in clone 4, from
2.6 to 8 nrM (Figure 4b).
Sensitisation ofneighbouring cells
Addition of a small fraction of clone 4 cells, markedly sen-
sitised neighbouring parental cells to the action of 5'-DFUR
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Fgre 3 (a) Representative in vitro dose-response curve of the
dThdPase transfected clone 4 to the prodrug of 5-FU, 5'-deoxy-5-
fluorouridine. in the absence (0) or presence of exogenously
added thymidine, at a concentration of I JLM (A), 3 IM (0) and
1O LM (O). Per cent growth inhibition is relative to drug-free
controls and determined using the MTT assay. Error bars repre-
sent the s.d. of eight wells. (b) Representative in vitro dose-
response curve of the parental MCF-7 cell line to the prodrug of
5-FU, 5'-deoxy-5-fluorouridine, in the absence (0) or presence of
exogenously added thymidine, at a concentration of 1 jAM (A),
3 gM (0) and 10 gM (O). Per cent growth inhibition is relative to
drug-free controls and is determined using the MfTT assay. Error
bars represent the s.d. of eight wells.
(Figure 5). The IC^_ of a population containing a 20:80
mixture of clone 4 and parental cells was reduced 10-fold.
This represents a significant in vitro 'bystander' killing effect
at a concentration at which the parental line is refractory to
the effects of 5'-DFUR.
dThdPase activity ofnormal and malignant breast tissue
Considerable heterogeneity was found in both the normal
and tumour cytosol samples, although dThdPase activity was
consistently elevated in the breast tumour cytosols (P<
0.0002). Values ranged from 46.5 to 929 nmol h-' mg-1
(median 273 nmol h-' mg-1), while normal tissue cytosols
displayed a more modest variability, ranging from 1.6 to
47 nmol h-' mg-1 (median 10.6 nmol h- mg'). However
none of the breast tumour cytosols showed elevations in
dThdPase activity of the order of that found for clone 4,
whilst clone 7 represents the levels at the upper third of the
tumour dThdPase range (Figure 6). dThdPase activity did
not correlate with oestrogen receptor (ER) or epidermal
[5-FUdR] (gM)
Figwe 4 (a) Representative in vitro dose-response curve of the
parental MCF-7 cell line to 5-fluoro-2'-deoxyuridine, in the
absence (0) or presence of exogenously added thymidine, at a
concentration of 1 gAM (A) and 3 gM (0). Per cent growth inhibi-
tion is relative to drug-free controls and is determined using the
MTT assay. Error bars represent the s.d. of eight wells. (b)
Representative in vitro dose-response curve of the dThdPase-
transfected clone 4 cell line to 5-fluoro-2'-deoxyuridine, in the
absence (0) or presence of exogenously added thymidine, at a
concentration of I iLm (A) and 3gM (0). Per cent growth inhibi-
tion is relative to drug-free controls and is determined using the
MUT assay. Error bars represent the s.d. of eight wells.
growth factor receptor (EGFR) status in either the tumour
or normal tissue samples.
Expression of dThdPase is elevated in many malignant
tumours, but a wide range of activities have been reported
(Zimmerman et al., 1964; Yoshimura et al., 1990). This
heterogeneity was confirmed by dThdPase enzyme assay of a
sample group of breast tumour cytosols prepared from
excision biopsies. We transfected dThdPase into a breast
cancer cell line to reproduce the range found in human breast
tumours and assess its contribution to drug resistance and
potential gene therapies. dThdPase activity per mg of total
cytosolic protein in the breast tumour samples showed a
20-fold range of elevated activities, which were consistently
greater (mean 27-fold) than that found for normal breast
tissue cytosols (Figure 6).
Two of the selected clones had elevated levels of dThdPase
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Figure 5 Plot of change in the mean IC50 value of the parental
MCF-7 cell line for 5'-deoxy-5-fluorouridine with increasing pro-
portions (%0) of clone 4 cells in vitro. ICR, values are the mean of
at least three independent experiments ± s.e.m., as determined
using the MTT assay.
activity and expressed a 45 kDa protein that was detected
with anti-dThdPase antibody. Increased expression of this
enzyme sensitised the human MCF-7 breast cell line to 5'-
DFUR in vitro. Clone 4, which showed a 90-fold increase in
dThdPase activity (with respect to the release of thymine
from dThd), had a 165-fold reduced IC50 value for 5'-DFUR
compared with the parental line. Conversion of the prodrug
5'-DFUR to 5-FU by the cell lysate preparation of clone 4
was 67-fold greater than that of the parental line. Clone 7
had a 2.4-fold differential in the IC50 value for 5'-DFUR
relative to the parental line. However, this difference was also
reflected in the ability of the cell lysate to catalyse the
formation of 5-FU from 5'-DFUR, being 5.6-fold greater
than that of the parental line. The degree of sensitivity
appears to be related to the capacity of the dThdPase to
phosphorolytically cleave the prodrug 5'-DFUR to yield the
metabolically active drug 5-FU. An exact correlation was not
obtained, probably because of variables in the different
assays (e.g. cell extracts dThdPase activity is assayed over
16 h vs in vitro sensitivity over 7 days). Comparison of our
observations of the relative increases in dThdPase expression
in tumour samples in relation to our in vitro results indicates
that an exploitable therapeutic differential exists between nor-
mal and tumour tissue with respect to 5'-DFUR treatment,
but the heterogeneity of overexpression in malignant tissue
suggests that tumour dThdPase profiling could be an impor-
tant component of patient selection programmes.
Circulating dThd is present in the plasma of individuals at
0.1-0.2 JLm (Shaw et al., 1988a,b). While the degree and
extent of vascularisation of a solid tumour largely dictates
the bioavailability of such nutrients, dThd availability in the
microenvironment of a tumour may become elevated as a
result of release from dying cells. Such increased bioavaila-
bility of dThd could modulate the efficacy of the prodrug
5'-DFUR by inhibiting the dThdPase-mediated cleavage to
the active agent, 5-FU. However, we showed that even levels
of dThd 50- to 100-fold greater than those detectable in
plasma could not fully reverse the effect of 5'-DFUR, and
1M dThd had only a marginal effect. The cytotoxic effects of
5-FU are thought to be mediated, in part, by the inhibition
of thymidylate synthase, through the anabolism of 5-FU to
5-FdUMP (Danenberg et al., 1974; Santi and McHenry.
Fue 6 Relative dThdPase actiVity (nmol thymine released
h-'mg-' protein) of the parental MCF-7. clone 4 and 7 lysates
relative to 12 breast tumour and ten normal breast cytosols.
dThdPase activity was measured spectrophotometrically follow-
ing 16 h incubation in 10 mm thymidine. 10 mm potassium phos-
phate pH 7.4 (37C). The total protein content of cytosols was
determined against a high-grade BSA standard, using the Bio-
Rad protein dye assay. dThdPase activity and protein content
were determined independently at least twice and the mean values
are shown.
1972). However, the addition of 150 gM dThd did not
influence the toxicity of 5-FU in the MCF-7 cell line,
indicating that this is not an important mechanism of toxicity
for MCF-7 cells (Kufe and Major, 1981). Thus the observed
reversal of 5'-DFUR toxicity by dThd in the clone 4 and 7
cell lines is mediated at the level of competition for prodrug
activation, rather than modulating the cytotoxicity of the
released 5-FU.
The IC50 values of 5-FUdR for the parental and trans-
fected cell lines were not significantly different, suggesting
that 5-FUdR is probably not an important substrate for the
phosphorolytic activity of dThdPase. However, the dThdPase
activity of the clones could significantly reverse the capacity
of dThd to rescue the cells from the toxic effects of 5-FUdR
(Nayak, 1992). This suggests that the phosphorolytic break-
down of dThd by dThdPase renders it metabolically
unavailable to bypass the inhibition of thymidylate synthase
or to ultimately compete with 5-FdUTP for incorporation
into DNA. Thus, it is possible that in vivo levels of dThdPase
could contribute to 5-FUdR response. If so. these cases may
respond well to 5'-DFUR treatment.
The requirement for dThdPase in the sensitisation to 5'-
DFUR has recently been confirmed by transfecting dThdPase
into human KB epidermoid carcinoma cells (Haraguchi et
al., 1993). We furthered this observation by establishing that
recombinant dThdPase can catalyse the phoshorolytic clea-
vage of 5'-DFUR to release 5-FU. This takes account of
potential differences between substrate specificity for the
thymine-2'-deoxyriboside and the 5-fluorouracil-5'-deoxyribo-
side, and demonstrates a direct role for dThdPase in the
sensitisation to 5'-DFUR. In contrast to the MCF-7 cell line,
the KB epidermoid parental line expressed no endogenous
dThdPase activity and the level of dThdPase activity confer-
red upon the clone by transfection was relatively low
(168 nmol h-' mg-'). This was reflected in the 19-fold
differential in IC_ values for 5'-DFUR. The transfection of
dThdPase into a cell line which has some endogenous
dThdPase activity, to sensitise the carcinoma cells further,
more accurately reflects the potential in vivo situation with
respect to enhancing the sensitivity of a tumour mass in situ,
through delivery of the dThdPase cDNA sequence under the
control of a suitable tissue-specific promoter. Such an app-
roach may help to overcome the heterogeneity of elevated
dThdPase expression observed in some malignant tissues.
A significant 'bystander' killing effect was observed for
5'-DFUR in the mixing experiments. suggesting that the
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active drug. 5-FU. can diffuse from its site of formation and
exert its effects upon neighbouring cells in vitro. It has been
suggested that the main pathway for the bystander effect is
via gap junctions (Freeman et al.. 1993). and this is the case
for phosphorylated metabolites (Bi et al.. 1993). However
5-FU can diffuse via a facilitated transporter, which may be
an advantage if gap junctions are down-regulated. Therefore.
the targeting of a tumour mass with a tissue-specific
promoter-driven dThdPase sequence in vivo may not require
the transduction of every tumour cell for effective killing of
neighbouring cells to occur. Advances in the efficiency of
gene deliverv through the use of techniques such as receptor-
mediated endocytosis and replication-incompetent adenovirus
co-internalisation (Cotten et al., 1992; Christiano et al., 1993)
may make dThdPase a suitable gene for prodrug therapies.
Potentially more important. such delivery protocols have
resulted in very favourable increases in the level of expression
of reporter genes. Comparative analysis of the parental and
transfected lines response to 5'-DFUR, and their differing
levels of dThdPase expression, suggests that increased levels
of expression may result in a considerable therapeutic gain in
vivo.
Another prodrug-enzyme-activated model, using the ex-
pression of cytosine deaminase to release 5-FU from the
prodrug 5-fluorocytosine (Huber et al., 1993), illustrates the
marked therapeutic advantages that can be achieved with
such approaches in vivo. However the 5'-DFUR dThdPase
model may prove to be supenror since co-metabolism of
endogenous dThd. although in direct substrate competition
with 5'-DFUR if present at 10- to 100-fold physiological
excess (1-1O pM). could nevertheless enhance the cytotoxicity
of the activated drug in a number of ways. Phosphorolytic
cleavage of dThd by dThdPase would render it metabolically
unavailable to bypass the inhibition of de novo synthesis and
to compete with FdUTP for incorporation into DNA (Major
et al.. 1982). The 'thymidine-less' state resulting from the
inhibition of thymidylate synthetase by FdUMP would make
tissues expressing dThdPase sensitive to the depletion of
salvageable dThd. limiting any potential 'rescue' from the
dThd-less-induced stress and its associated cytotoxicity
(Houghton et al.. 1993). Furthermore. dThdPase may en-
hance the formation of FdUMP through the reversible addi-
tion of deoxyribose 1-phosphate to the enzymatically released
5-FU (Schwartz et al.. 1994). Depletion of the available dThd
would also serve to increase local concentrations of thymine.
which would competitively inhibit the catabolism of 5-FU by
dihydrouracil dehydrogenase. potentially extending its half-
life within the tumour mass (Santelli and Valeroti. 1980).
Prolonging the duration and intensity of tumour tissue
exposure to 5-FU. and its associated anabolites. has been
shown to limit the occurrence of resistant clones associated
with suboptimal chronic exposures in vitro (Sobrero et al..
1993). This may have implications in restricting the develop-
ment of acquired resistance in vivo. Increasing the duration of
5-FU exposure has also been shown to enhance significantly
the cytotoxicity of the biomodulators leucovorin and inter-
feron x2a in vitro (Houghton et al., 1993).
5'-DFUR. but not 5-FU. also possesses other antipro-
liferative-independent characteristics which may prove clini-
cally advantageous. For example it has anti-cachectic activity
(Tanaka et al.. 1990; Eda et al.. 1991) and has been reported
to inhibit metastases in an artificial murine Lewis lung car-
cinoma metastasis model (Bertram. 1995).
In conclusion, our results show that dThdPase is a can-
didate gene for gene-directed enzyme/prodrug therapy. and
cell lines with endogenous dThdPase can be further sensitised
to 5'-DFUR. This approach could also overcome one
mechanism of 5-FUdR resistance.
These data also suggest that selection of patients for 5'-
DFUR therapy based on tumour levels of dThdPase should
be considered.
Abbreviatioas PD-ECGF. platelet-derived endothelial cell growth
factor; dThdPase. thymidine phosphorylase; 5-FU. 5-fluorouracil;
5'-DFUR, 5'-deoxy-5-fluorouridine. (doxifluridine. Furtulon); 5-
FUdR. 5-fluoro-2'-deoxyuridine: 5-FdUMP, 5-fluoro-2'-deoxyuridine
5'-monophosphate; 5-FdUTP. 5-fluoro-2'-deoxyuridine 5'-triphos-
phate; dThd. thymidine; dTMP, thymidine 5'-monophosphate; MTT,
3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bromide; PBS,
phosphate-buffered saline: IC50, concentration of drug at which cell
growth is inhibited by 50%: SDS. sodium dodecyl sulphate: cDNA,
complementary DNA.
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